Aloumanis K, Karras D, Drossinos V, Korelis E, Polydorakis A
Department of Medical Research, Pharmaserve-Lilly, Kifissia, 14564 Athens, Greece.
J Osteoporos. 2011;2011:510398. doi: 10.4061/2011/510398. Epub 2011 Sep 20.
Objective. To evaluate fracture incidence, effects on health-related quality of life(QoL), back pain (BP) occurrence and treatment compliance in Greek post-menopausal osteoporotic women treated with teriparatide (TPTD) for up to 18 months, in a naturalistic setting. Methods. 301 patients provided baseline information on demographic characteristics, fracture history, osteoporosis-related medication and risk factors. During treatment, QoL and BP severity were evaluated. Results. Mean (SD) age was 69.5 (±8.5) years. Fracture history was reported by 92.5% of patients. Incidence of fractures (per 10,000 patients/years) ranged from 402 during 0-6 months of treatment, to 346 during 12-18 months. All 5 dimensions of QoL showed improvement. At baseline and 18 months, BP was reported by 93.2% and 64.2% of patients, respectively. BP and limitation of activities were quantified as moderate or severe by 89.9% and 62.3% of patients at baseline versus 32.4% and 14.8% at 18 months. Patients on treatment at 6, 12, 17, and 18 months were 92.6%, 88.3%, 79.6%, and 36.5%, respectively. Conclusions. In the Greek EFOS study cohort, patients prescribed TPTD were severely osteoporotic, with considerable health-related problems. Significant improvements in QoL and BP together with low fracture rates and high compliance have been recorded during treatment.
目的。在自然环境中，评估希腊绝经后骨质疏松女性接受特立帕肽（TPTD）治疗长达18个月时的骨折发生率、对健康相关生活质量（QoL）的影响、背痛（BP）的发生情况及治疗依从性。方法。301例患者提供了关于人口统计学特征、骨折史、骨质疏松相关药物及危险因素的基线信息。在治疗期间，对QoL和BP严重程度进行评估。结果。平均（标准差）年龄为69.5（±8.5）岁。92.5%的患者报告有骨折史。骨折发生率（每10,000患者/年）在治疗的0 - 6个月期间为402，在12 - 18个月期间为346。QoL的所有5个维度均有改善。在基线和18个月时，分别有93.2%和64.2%的患者报告有BP。在基线时，89.9%的患者将BP和活动受限量化为中度或重度，而在18个月时这一比例分别为32.4%和14.8%。在6、12、17和18个月接受治疗的患者比例分别为92.6%、88.3%、79.6%和36.5%。结论。在希腊EFOS研究队列中，接受TPTD治疗的患者骨质疏松严重，存在相当多的健康相关问题。治疗期间记录到QoL和BP有显著改善，同时骨折率低且依从性高。
